Martin B. Leon works in Interventional / Structural Cardiology affiliated with NewYork–Presbyterian Hospital.
Martin B. Leon, MD, is Professor of Medicine at Columbia University Irving Medical Center and serves as Chief Innovation Officer and Director of the Cardiovascular Data Science Center for the Division of Cardiology. He practices as an interventional cardiologist at NewYork-Presbyterian Hospital and is Founder and Chairman Emeritus of the Cardiovascular Research Foundation. He has been national principal investigator for over 50 clinical trials, including the PARTNER trials evaluating transcatheter aortic-valve replacement.
2,008 pubs · 176,408 cites · h-index 188
MD
Yale University School of Medicine
1975
BS
State University of New York at Stony Brook
1971
Cardiology Fellowship
Yale-New Haven Hospital
1982
Professor of Medicine; Chief Innovation Officer and Director, Cardiovascular Data Science Center
Columbia University Irving Medical Center / NewYork-Presbyterian Hospital · 2004 - Present
Director, Columbia Interventional Cardiovascular Care
Columbia University Irving Medical Center · 2010 - 2023
Director of Cardiovascular Research and Education
Lenox Hill Heart and Vascular Institute · 1999 - 2004
Director of Clinical Research; Clinical Professor of Medicine
Washington Cardiology Center / Georgetown University Medical Center · 1990 - 1999
Senior Investigator and Director of Catheterization Laboratories
National Heart, Lung, and Blood Institute, National Institutes of Health · 1983 - 1990
May offer a less invasive septal reduction option in HOCM; leaves open the need for randomized trials before clinical adoption.
Chair of cardiovascular medicine, Cleveland Clinic · Cleveland Clinic
First, in these reported clinical trials with imaging endpoints, approximately 18% of patients were not able to undergo magnetic resonance imaging (MRI), which can be an important consideration when designing studies with primary imaging endpoints.
Journal of the American College of CardiologyLansky et al.
In this prespecified secondary analysis of the FAVOR III China trial, QFR-guided PCI significantly reduced 3-year MACE compared to angiography-guided PCI in patients with multivessel disease, with consistent directional benefit regardless of MVD status.
Transcatheter tricuspid valve replacement nearly eliminates severe tricuspid regurgitation, which is associated with reduced venous congestion, right ventricular reverse remodeling, and improved forward stroke volume at 1 year.
Insulin-requiring diabetes mellitus is a strong independent predictor of in-hospital mortality, target lesion revascularization, and late cardiac events following elective coronary stenting, whereas non-insulin-treated diabetics have similar outcomes to nondiabetic patients.
Meta-analysis reveals reduced all-cause mortality with complete revascularization after myocardial infarction, highlighting potential survival benefits over culprit-only treatment.
Director of clinical cardiology, Brigham and Women's Hospital
Manipulation of the left main in this particular area is fraught with complications and relatively high rates of recurrent events.
Journal of the American College of CardiologyChen et al.
This consensus document establishes standardized clinical trial principles, endpoint definitions, and a novel grading scheme for the evaluation of paravalvular leak closure devices.
Mild and trace valvular abnormalities in older adults are associated with subclinical cardiac remodeling and elevated biomarkers, suggesting they have pathophysiological importance.
Randomized double-blind trial demonstrates reduced repeat revascularization with sirolimus-eluting stents in coronary disease, indicating long-term efficacy without increased safety risks.
Cardiologist, Norwich University Hospital · Norwich University Hospital
There is a lot of debate and controversy about how we best define type 4a MIs, with previous studies like EXCEL and ISCHEMIA using their own definitions. Depending on the definition used, this can change the outcomes of these trials quite significantly.
Journal of the American College of CardiologyGregson et al.
Interventional cardiologist, L'Hôpital de la Tour, Geneva · L'Hôpital de la Tour
I think the picture is getting clearer and clearer: you try and stay away from that second stent.
Journal of the American College of CardiologyGénéreux et al.
Observational study reveals improved device success with new-generation prostheses in bicuspid aortic valve stenosis, indicating enhanced safety.
Clinical evaluation reveals left ventricular mass regression following transcatheter aortic valve replacement, indicating favorable reverse cardiac remodeling.
Interventional cardiologist, Tel Aviv University
I was troubled to publish these data given the potential confusion it can create, but we must understand that in the Registry, redo-TAVR for probable device failure constituted only 0.22% of the overall 63,876 TAVR procedures. This low rate reflects the relative durability of the valves and also the competing risk of mortality in the elderly and high-risk patients undergoing TAVR so far.
Journal of the American College of CardiologyLandes et al.
Clinical review highlights diagnostic and management strategies for valvular heart disease in octogenarians, indicating the growing importance of tailored interventions.
TAVR provides comparable intermediate-term hemodynamic durability to SAVR, with larger effective orifice areas but higher rates of paravalvular regurgitation.
